<span style="font-size:12.0pt;font-family: "Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language: EN-IN;mso-fareast-language:EN-IN;mso-bidi-language:AR-SA" lang="EN-IN">Glucopyranosyl derivatives of 4-aminoquinoline and 2-methylimidazo[1,2-<i style="mso-bidi-font-style: normal">α</i>]-pyridine as potent reversible proton pump inhibitors^†</span>

635-638Amongst a number of 4-aminoquinoline and 2-methylimidazo[1,2,-a]-pyridine derivatives examined 2-[3-butyryl-4-(2-methylphenylamino)quinoline-8-yloxy]ethyl  2,3,4,6-tetra-<i style="mso-bidi-font-style: normal">O-acetyl<span style="font-size:12.0pt;font-family: " times="" new="" roman";mso-fareast-font-family:hiddenhorzocr;mso-ansi-language:en-in;="" mso-fareast-language:en-in;mso-bidi-language:ar-sa"="" lang="EN-IN">-β-D-glucopyranoside and 3-ethoxycarbonyl-2-methylimidazo[1,2-α]pyridine-8-yl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside have been found to be good reversible proton pump inhibitors.</span

Novel euglycemic and hypolipidemic agents: Pyridine containing unsaturated thiazolidinediones

403-406Pyridyl containing 2,4-thiazolidinediones having cyclic amine as linker have been synthesized. Both unsaturated thiazolidinedione <span style="font-size:15.5pt; mso-bidi-font-size:8.5pt;font-family:" times="" new="" roman";mso-fareast-font-family:="" "times="" roman";mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa"="">6<span style="font-size:15.5pt;mso-bidi-font-size: 8.5pt;font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"=""> and saturated thiazolidinedione 5 and their various salts have been evaluated in db/db mice for euglycemic and hypolipidemic effects. The maleate salt of TZD 6a is found to be a very potent euglycemic and hypolipidemic compound.</span